Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation and Depletion (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Depreciation and Depletion data on record, last reported at $100000.0 in Q3 2025.

  • For Q3 2025, Depreciation and Depletion fell 50.0% year-over-year to $100000.0; the TTM value through Sep 2025 reached $400000.0, down 50.0%, while the annual FY2024 figure was $700000.0, 12.5% down from the prior year.
  • Depreciation and Depletion reached $100000.0 in Q3 2025 per ACRS's latest filing, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $200000.0 in Q1 2021 and bottomed at $100000.0 in Q4 2022.
  • Average Depreciation and Depletion over 5 years is $173684.2, with a median of $200000.0 recorded in 2021.
  • Peak YoY movement for Depreciation and Depletion: plummeted 50.0% in 2022, then surged 100.0% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $200000.0 in 2021, then tumbled by 50.0% to $100000.0 in 2022, then soared by 100.0% to $200000.0 in 2023, then tumbled by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $100000.0 in Q3 2025, $100000.0 in Q2 2025, and $100000.0 in Q1 2025.